Six weeks of federal activity bear on the products licensed practices source for aesthetic, wellness and longevity programs. The largest change is an HHS policy for 503A compounding with six peptides, published 30 October 2026, with comments open until 13 November. [1, 2] The rest of the period brought FDA warning letters that turn on how products are described, a renewed advisory committee for cell and tissue products, a final guidance on potency for cellular products, and a DEA deadline that falls at the end of the year. [3, 4, 5, 6, 7]
Regulatory Position
Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are marketed. [5, 8] The HHS document is an enforcement discretion policy that HHS describes as a draft and interim; it establishes no rights and binds neither HHS nor the public. [1] ExaVeyra is a supplier, and the prescriber decides whether any preparation suits an identified patient.
HHS Set Ten Conditions for 503A Compounding With Six Peptides
On 30 October 2026 HHS published a policy describing when it does not intend to take enforcement action against a state-licensed pharmacy, a Federal facility or a licensed physician compounding with one of six peptides: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. [1, 8] The policy applies while FDA develops the 503A bulks list through rulemaking, and HHS may revisit it if a safety signal or a product quality issue arises. [1] All ten conditions must be present for each compounded product. [8]
- The bulk substance is one of the six in Appendix A.
- It matches the identity in Appendix B and is used only by the routes listed there.
- It comes from a facility registered with FDA under section 510, with a valid certificate of analysis that follows FDA’s testing criteria.
- The original manufacturer is registered with FDA and follows CGMP, and the physical location of its facility is listed on the certificate; a registered repacker or reseller in the chain must have validated that manufacturer and its certificate.
- The compounder reports products compounded, serious adverse events and product quality issues to FDA through MedWatch and to the states involved.
- The label reads “This is a compounded drug product. Not for resale.”
- Each product contains a single active ingredient from Appendix A, so a blend falls outside the policy.
- An oral form is supported by documentation of adequate human oral bioavailability for that formulation.
- The only device co-packaged with or containing the product is an FDA 510(k)-cleared syringe.
- The product meets every other requirement of the Federal Food, Drug, and Cosmetic Act, including the patient-specific prescription.
The route limits in Appendix B are specific. BPC-157 covers subcutaneous, intramuscular, oral and topical forms; TB-500 and MOTS-c cover subcutaneous or intramuscular injection; epitalon covers subcutaneous or intramuscular use in intermittent courses; semax covers intranasal use; and KPV covers topical and oral forms. [8] No intravenous route appears for any of the six, which is why an intravenous form falls outside the policy. [8] Appendix B also fixes each peptide’s form: the acetate for BPC-157, TB-500, epitalon, KPV and MOTS-c, and the free base for semax. [8]
| Peptide | Routes within the policy (Appendix B) |
|---|---|
| BPC-157 | Subcutaneous, intramuscular, oral, topical |
| TB-500 | Subcutaneous or intramuscular |
| MOTS-c | Subcutaneous or intramuscular |
| Epitalon | Subcutaneous or intramuscular, intermittent courses |
| Semax | Intranasal |
| KPV | Topical and oral |
Comments on the HHS Policy Close on 13 November
The notice allows written comments for two weeks after its 30 October publication, and the regulations.gov docket lists the close as 11:59 p.m. Eastern on 13 November 2026. [1, 2] Comments go to Docket HHS-OASH-2026-0496. [2] Pharmacies and prescribers with characterization data or reporting experience can use the docket to put that evidence before the agency while FDA prepares its rulemaking. [8]
FDA’s 503A Category Lists Are Unchanged Since May
FDA’s list of nominated bulk substances, updated 14 May 2026, places GHK-Cu for routes other than injection back in category 1, after a nominator clarified that it had withdrawn only the injectable nomination. [9] FDA states that it intends to consult the Pharmacy Compounding Advisory Committee on GHK-Cu before the end of February 2027. [9] On FDA’s safety-risk page, current as of 22 April 2026, the six HHS peptides and injectable GHK-Cu sit in the table of withdrawn nominations. [10]
These are FDA interim category policies, separate from the HHS policy. GHK-Cu is not among the six HHS peptides, so the two documents apply to different substances and different routes. [8, 9]
Advisory Committee Votes Leave the 503A Bulks List Unchanged
FDA’s Pharmacy Compounding Advisory Committee, which meets in public with a docket open for written comments (Fig. 1), met on 23 and 24 July 2026 to consider placing BPC-157, KPV, TB-500, MOTS-c, emideltide, epitalon and semax on the 503A bulks list. [8, 11] For each of the six covered peptides, the HHS policy records that FDA’s Center for Drug Evaluation and Research recommended against listing and the committee voted in favor. [8] A committee vote is advice to the agency: the codified list at 21 CFR 216.23, last amended in 2019, names no peptide, and the statute places substances on it through rulemaking. [12, 13]

FDA Renewed Its Cell, Tissue and Gene Therapy Advisory Committee
On 14 October 2026 FDA announced the renewal of the charter of the Cellular, Tissue, and Gene Therapies Advisory Committee, which now runs to 28 October 2028. [3] The committee advises FDA on human cells, human tissues and gene therapy products, so its future agendas are where questions about cell and tissue derived products are likely to be aired. [3] The renewal itself changes no rule for products practices buy today.
Warning Letters Turned on How Products Are Described
On 27 October 2026 FDA’s Center for Biologics Evaluation and Research posted two warning letters, dated 25 September and 13 October. [4, 14] In the October letter, the agency found that umbilical cord derived and exosome products intended for allogeneic use were unapproved new drugs and unlicensed biologics, basing that view partly on statements on the seller’s website, and found that the umbilical cord product did not meet the homologous use criterion in 21 CFR 1271.10. [4, 15] The September letter reached the same conclusions for embryonic stem cell and placenta-derived products sold online. [14]
On 30 October FDA’s Center for Drug Evaluation and Research (Fig. 2) issued a letter to a telehealth seller whose website described compounded medications as FDA-approved. [5] The agency found the claims false or misleading under sections 502(a) and 502(bb) of the Act, stated that compounded drug products are not FDA-approved, and said that disclaimers do not cure a misleading overall impression. [5]

For Practices
In each letter the agency weighed what a seller said about a product alongside the product itself. [4, 5, 14] A practice can check that a supplier’s materials match each product’s labeled status, such as research use only or topical cosmetic use, and that compounded products are described as compounded.
FDA Finalized Its Potency Guidance for Cellular Products
On 3 November 2026 FDA finalized Potency Assurance for Cellular and Gene Therapy Products, replacing the December 2023 draft. [6] The guidance applies to licensed and investigational cellular and gene therapy products regulated as biological products, and describes how a potency strategy is built over development and confirmed at lot release. [6] It is useful context when a supplier uses the word potency, because the guidance ties the term to measured assays and lot release testing. [6]
The DEA Telemedicine Flexibilities End on 31 December
The fourth temporary extension of the DEA and HHS telemedicine flexibilities for prescribing controlled medications runs from 1 January to 31 December 2026, and no further DEA rule on telemedicine prescribing appeared in the Federal Register between 1 October and 9 November. [7] Practices that prescribe controlled substances by telemedicine without a prior in-person visit face that date unless DEA acts again. The date matters for controlled substances, such as the anabolic steroids that 21 CFR 1308.13 places in schedule III. [7, 16]
Three Smaller Items Complete the Period
- 20 October: FDA finalized guidance on identity and safety information for new dietary ingredient notifications, which concerns dietary supplements rather than compounded drugs. [17]
- 23 October: FDA finalized questions and answers on its mandatory recall authority for cosmetics, relevant to products labeled as topical cosmetics. [18]
- 30 October: FDA revised its draft guidance on drug delivery performance for devices and combination products, with comments due 28 January 2027. [19]
Dates to Watch Next
| Date | What happens |
|---|---|
| 13 November 2026 | Comments close on the HHS peptide policy, Docket HHS-OASH-2026-0496 |
| 31 December 2026 | The current DEA telemedicine flexibilities end |
| 28 January 2027 | Comments due on FDA’s revised drug delivery device guidance |
| By end of February 2027 | FDA plans to consult its compounding advisory committee on GHK-Cu |
| No date set | FDA rulemaking on the 503A bulks list for the six peptides |
ExaVeyra Will Publish This Update Each Month
ExaVeyra works with licensed practices through a licensed 503A pharmacy partner on patient-specific prescriptions, with a certificate of analysis available on request for each lot. This update will appear each month, drawn from the Federal Register, FDA and other official sources. Practices with a question about a specific product, a certificate or a documentation requirement are welcome to ask the scientific team directly, and anyone can apply for a free account; NPI verification then unlocks the practitioner portal, exclusive resources and pricing.
Educational Disclaimer: This article is for educational purposes only and does not constitute medical or legal advice. It does not identify any material, compound, device setting or protocol as safe, effective or appropriate for any patient, and it is not intended to diagnose, treat, cure, or prevent any disease. Questions about a treatment belong with the reader’s own licensed provider. Exosome material is supplied for topical aesthetic use by licensed practitioners. No exosome product is FDA-approved for any use, and ExaVeyra Sciences makes no statement about administration, route, or outcome. Compounded medications are not FDA-approved. They are prepared by a 503A compounding pharmacy licensed by the Texas State Board of Pharmacy for an individual patient against that patient’s prescription, and are available to NPI-verified licensed practitioners only, in the states where the pharmacy is licensed. Product, device and brand names mentioned are trademarks of their respective owners and are used only to identify the products discussed. Their mention is not an endorsement, and those owners have not reviewed or endorsed this article. ExaVeyra Sciences is a supplier and takes no part in any diagnosis, treatment decision, or plan of care. Findings described are attributed to the peer-reviewed literature, trial registries and agencies cited. The content of these guides is provided for general informational purposes only. It does not constitute legal, medical, or regulatory advice, and does not establish that any particular product or practice is compliant. Regulatory requirements vary by state and depend on the circumstances of each practice. Each practitioner should consult their own legal counsel and the applicable state licensing boards before acting on anything stated here.
References
- 1.U.S. Department of Health and Human Services, Office of the Secretary. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances; notice of availability. Fed Regist. 2026;91(209):68526-68527. FR Doc. 2026-22192. RIN 0910-ZD94. https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substancesPrimary source, read in full 9 Nov 2026. Carries in this article: the publication date, the two-week comment window, and HHS’s description of the policy as a draft that is not binding.
- 2.Regulations.gov. Docket HHS-OASH-2026-0496, Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Documents posted 30 October 2026. https://www.regulations.gov/docket/HHS-OASH-2026-0496Docket listing, read 9 Nov 2026. Carries in this article: where comments are filed and the closing time of 11:59 p.m. Eastern on 13 November 2026.
- 3.U.S. Food and Drug Administration. Advisory Committee; Cellular, Tissue, and Gene Therapies Advisory Committee; Renewal. Fed Regist. 2026;91(197):65223-65225. FR Doc. 2026-20989. https://www.federalregister.gov/documents/2026/10/14/2026-20989/advisory-committee-cellular-tissue-and-gene-therapies-advisory-committee-renewalFederal Register notice. Carries in this article: the renewal announced on 14 October 2026 and the new expiration date of 28 October 2028.
- 4.U.S. Food and Drug Administration, Center for Biologics Evaluation and Research. Warning Letter CBER 26-729846, 13 October 2026, posted 27 October 2026. FDA Warning Letters database. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-lettersAgency warning letter, cited by letter number. Carries in this article: FDA’s finding that umbilical cord derived and exosome products for allogeneic use were unapproved new drugs and unlicensed biologics, and that one product failed the homologous use criterion.
- 5.U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Warning Letter MARCS-CMS 737905, 30 October 2026, posted 3 November 2026. FDA Warning Letters database. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-lettersAgency warning letter, cited by letter number. Carries in this article: FDA’s finding that claims describing compounded drugs as FDA-approved were false or misleading under sections 502(a) and 502(bb), and that disclaimers do not remove the impression.
- 6.U.S. Food and Drug Administration. Potency Assurance for Cellular and Gene Therapy Products; Guidance for Industry; Availability. Fed Regist. 2026;91(211):69259-69261. FR Doc. 2026-22427. Docket FDA-2023-D-4299. https://www.federalregister.gov/documents/2026/11/03/2026-22427/potency-assurance-for-cellular-and-gene-therapy-products-guidance-for-industry-availabilityFinal guidance notice. Carries in this article: that the guidance, finalized 3 November 2026, replaces the December 2023 draft and applies to licensed and investigational cellular and gene therapy products.
- 7.Drug Enforcement Administration and U.S. Department of Health and Human Services. Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications; temporary rule. Fed Regist. 2025;90(247):61301-61306. FR Doc. 2025-24123. Docket DEA-407. https://www.federalregister.gov/documents/2025/12/31/2025-24123/fourth-temporary-extension-of-covid-19-telemedicine-flexibilities-for-prescription-of-controlledTemporary rule. Carries in this article: that the current flexibilities run from 1 January to 31 December 2026.
- 8.U.S. Department of Health and Human Services. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A and Appendix B. October 2026. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdfPrimary source. Carries in this article: the six peptides, the ten conditions, the route limits for each peptide, and the committee and CDER positions recorded for each.
- 9.U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. Updated 14 May 2026. https://www.fda.gov/media/94155/downloadAgency list. Carries in this article: GHK-Cu for routes other than injection back in category 1, and FDA’s plan to consult the advisory committee on GHK-Cu before the end of February 2027.
- 10.U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Content current as of 22 April 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risksAgency web page, read 9 Nov 2026. Carries in this article: the table of withdrawn nominations, which lists the six peptides and injectable GHK-Cu.
- 11.U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee; Notice of Meeting. Fed Regist. 2026;91(73):20465-20467. FR Doc. 2026-07361. Docket FDA-2025-N-6895. https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-requestMeeting notice. Carries in this article: the 23 and 24 July 2026 meeting dates and the peptides placed before the committee.
- 12.Electronic Code of Federal Regulations. 21 CFR 216.23, Bulk drug substances that can be used to compound drug products in accordance with section 503A. Last amended February 19, 2019 (84 FR 4710). https://www.ecfr.gov/current/title-21/section-216.23Regulation. Carries in this article: the codified 503A bulks list, which names no peptide.
- 13.Federal Food, Drug, and Cosmetic Act § 503A, Pharmacy compounding. 21 U.S.C. § 353a. https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section353a&num=0&edition=prelimStatute. Carries in this article: that the bulks list is set through rulemaking.
- 14.U.S. Food and Drug Administration, Center for Biologics Evaluation and Research. Warning Letter CBER 26-729163, 25 September 2026, posted 27 October 2026. FDA Warning Letters database. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-lettersAgency warning letter, cited by letter number. Carries in this article: the same conclusions for embryonic stem cell and placenta-derived products sold online.
- 15.Electronic Code of Federal Regulations. 21 CFR 1271.10, Are my HCT/Ps regulated solely under section 361 of the PHS Act and the regulations in this part, and if so what must I do? https://www.ecfr.gov/current/title-21/chapter-I/subchapter-L/part-1271/subpart-A/section-1271.10Regulation. Carries in this article: the homologous use criterion an HCT/P must meet to be regulated solely under section 361.
- 16.Electronic Code of Federal Regulations. 21 CFR 1308.13, Schedule III. Current as of 5 November 2026. https://www.ecfr.gov/current/title-21/chapter-II/part-1308/section-1308.13Regulation. Carries in this article: that paragraph (f) places anabolic steroids, as defined in 21 CFR 1300.01, in schedule III.
- 17.U.S. Food and Drug Administration. New Dietary Ingredient (NDI) Notifications and Related Issues; Identity and Safety Information About the NDI: Guidance for Industry; Availability. Fed Regist. 2026;91(201):66336-66337. FR Doc. 2026-21453. https://www.federalregister.gov/documents/2026/10/20/2026-21453/new-dietary-ingredient-ndi-notifications-and-related-issues-identity-and-safety-information-aboutFinal guidance notice. Carries in this article: the 20 October 2026 date and that the guidance concerns dietary supplement notifications.
- 18.U.S. Food and Drug Administration. Questions and Answers Regarding Mandatory Cosmetics Recalls; Guidance for Industry; Availability. Fed Regist. 2026;91(204):66851-66852. FR Doc. 2026-21679. https://www.federalregister.gov/documents/2026/10/23/2026-21679/questions-and-answers-regarding-mandatory-cosmetics-recalls-guidance-for-industry-availabilityFinal guidance notice. Carries in this article: the 23 October 2026 date and FDA’s mandatory recall authority for cosmetics.
- 19.U.S. Food and Drug Administration. Essential Drug Delivery Performance Characteristics for Devices Intended to Deliver Drugs and Biological Products; Revised Draft Guidance for Industry; Availability. Fed Regist. 2026;91(209):68523-68525. FR Doc. 2026-22203. https://www.federalregister.gov/documents/2026/10/30/2026-22203/essential-drug-delivery-performance-characteristics-for-devices-intended-to-deliver-drugs-andRevised draft guidance notice. Carries in this article: the 30 October 2026 date and the 28 January 2027 comment deadline.
Image credits
- Fig. 1U.S. Food and Drug Administration, Wikimedia Commons (FDA Flickr), Public domain. ↩
- Fig. 2U.S. Food and Drug Administration, Wikimedia Commons (FDA Flickr), Public domain. ↩